Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) P/E Ratio History
Historical price-to-earnings valuation from 2025 to 2025
Loading P/E history...
DMAA Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 9, 2026, Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) trades at a price-to-earnings ratio of -189.3x, with a stock price of $10.60 and trailing twelve-month earnings per share of $0.25.
The current P/E is 91753% below its 5-year average of 0.2x. Over the past five years, DMAA's P/E has ranged from a low of 0.2x to a high of 0.2x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Financial Services sector median P/E of 13.3x, DMAA trades at a 1528% discount to its sector peers. The sector includes 776 companies with P/E ratios ranging from 0.0x to 197.4x.
Relative to the broader market, DMAA trades at a notable discount to the S&P 500 median P/E of 24.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our DMAA DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
DMAA P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $13M | 8.0Lowest | - | -4% | |
| $275B | 15.3 | 0.72Best | +8% | |
| $146B | 18.9 | - | -4% | |
| $356B | 85.0 | - | -1% | |
| $115B | 16.3 | - | +178%Best | |
| $896B | 41.3 | 1.43 | +96% | |
| $179B | 23.3 | 7.93 | +88% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
DMAA Historical P/E Data (2025–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | $10.27 | $49.29 | 0.2x | +1% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $10.20 | $49.21 | 0.2x | +0% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $10.02 | $49.14 | 0.2x | -1% |
Average P/E for displayed period: 0.2x
See DMAA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs DMAA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare DMAA vs BRK-A
Side-by-side business, growth, and profitability comparison vs Berkshire Hathaway Inc..
Start ComparisonDMAA — Frequently Asked Questions
Quick answers to the most common questions about buying DMAA stock.
Is DMAA stock overvalued or undervalued?
DMAA trades at -189.3x P/E, below its 5-year average of 0.2x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does DMAA's valuation compare to peers?
Drugs Made In America Acquisition Corp. Ordinary Shares P/E of -189.3x compares to sector median of 13.3x. The discount suggests lower growth expectations or higher risk.
What is DMAA's PEG ratio?
DMAA PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2025-2025.